Oligonucleotide based-strategies for allergy with special reference to siRNA

Abstract

Background: Allergic diseases are a significant global health care problem. Current pharmacological approaches address symptoms but do not alter the underlying immune dysregulation. Current allergen-specific immunotherapy has several drawbacks. Therefore, approaches that attenuate allergic responses safely and effectively at the level of upstream causative events are desirable. Oligonuleotide-based therapies [CpG DNA, antisense oligonucleotides, and small interfering RNA (siRNA)] are promising approaches. Objective/methods: We review developments in oligonucleotide-based therapies and the potential of siRNA for treating allergy. Results/conclusions: Strategies with oligonucleotides basically aim to reduce T helper type 2 (Th2) responses. It is controversial whether the reduction of Th2 responses does, in fact, attenuate allergic diseases. Increased understanding of allergic mechanisms will enhance the efficacy of oligonucleotide-based therapy

Keywords::

• allergy
• CpG DNA
• dendritic cells
• gene silencing
• RNA interference
• siRNA

Notes